12 October 2007

Trading Update : Building Confidence

The Director’s confidence with Cyprotex’s core operations continued to build during the third quarter of 2007. The Group enters the final three months of its year on an optimistic note.

Historically the final quarter has been the strongest period of Cyprotex’s financial year. Moreover, management is pleased to confirm that its customer base has continued to expand rapidly. Included within the high number of new MSA (Master Services Agreements) recently signed, and taking the Group’s ‘active customer list’ beyond 150 pharmaceutical and biotech companies, are several international majors. Strict confidentiality agreements preclude Cyprotex from naming individual clients, but the company can now confirm it is currently contracted to work for six out of the world’s ‘top ten’ global pharmaceutical companies. The scale and visibility that strong working relationships with such partners are capable of providing, is key to proving Cyprotex’s business plan. The management is pleased to report an exceptional level of repeat business, while also being asked to tenders for more long-term contract work as well as project specific collaborations.

Cyprotex presently holds an adequate cash resource whilst also retaining a significant, unused banking facility. Based on current momentum, management sees the opportunity for modest cash generation to expand this ‘cushion’ still further during the final three months of the 2007.

For further information:
Cyprotex PLC
Robert Morrison Atwater, CEO
Russell Gibbs, CFO
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Nomura Code Securities Limited
Charles Walker, Corporate Finance
Tel: +44 (0)20 7776 1200
cew@nomuracode.com
www.nomuracode.com

Media Enquires:
WMC Communications
Alex Glover
Tel: +44 (0)20 7930 9030
alex.glover@wmccommunications.com